In a post hoc 4-year analysis of the phase 3 TOPAZ-1 trial (685 adults with advanced biliary tract cancer), durvalumab plus gemcitabine–cisplatin gave median OS 13.0 vs 11.4 months with placebo (HR 0.75); 48-month OS 11.8% vs 4.3%, with similar serious adverse events.
Secondary analysisn = 685
Oh et al. Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial